
## Maximilian Koblischke

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7766603/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity. Annals of the Rheumatic Diseases, 2021, 80, 1345-1350.	0.9	211
2	SARS-CoV-2 mutations in MHC-I-restricted epitopes evade CD8 <sup>+</sup> T cell responses. Science Immunology, 2021, 6, .	11.9	143
3	Comparison of SARS-CoV-2 Antibody Response 4 Weeks After Homologous vs Heterologous Third Vaccine Dose in Kidney Transplant Recipients. JAMA Internal Medicine, 2022, 182, 165.	5.1	100
4	Dynamics of CD4 T Cell and Antibody Responses in COVID-19 Patients With Different Disease Severity. Frontiers in Medicine, 2020, 7, 592629.	2.6	54
5	Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomised controlled trial. Annals of the Rheumatic Diseases, 2022, 81, 687-694.	0.9	43
6	B Cell Depletion and <scp>SARSâ€CoV</scp> â€⊋ Vaccine Responses in Neuroimmunologic Patients. Annals of Neurology, 2022, 91, 342-352.	5.3	29
7	Structural Influence on the Dominance of Virus-Specific CD4 T Cell Epitopes in Zika Virus Infection. Frontiers in Immunology, 2018, 9, 1196.	4.8	25
8	Protein structure shapes immunodominance in the CD4 T cell response to yellow fever vaccination. Scientific Reports, 2017, 7, 8907.	3.3	18
9	CD4 T cell responses to flaviviruses. Journal of Clinical Virology, 2018, 108, 126-131.	3.1	13
10	CD4 T Cell Determinants in West Nile Virus Disease and Asymptomatic Infection. Frontiers in Immunology, 2020, 11, 16.	4.8	7
11	Immunogenicity of COVID-19 Vaccinations in Hematological Patients: 6-Month Follow-Up and Evaluation of a 3rd Vaccination, Cancers, 2022, 14, 1962.	3.7	6